Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis Yee-Ming Melody CheungWei WangOle-Petter Riksfjord Hamnvik Review Article 13 January 2022 Pages: 1795 - 1812
Pediatric glioblastoma: mechanisms of immune evasion and potential therapeutic opportunities Rosy NjonkouChristopher M. JacksonDavid S. Hersh Review Article 12 January 2022 Pages: 1813 - 1822
The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents Carlos Zamora AtenzaGeòrgia AngueraMargarita Majem Original Article 05 January 2022 Pages: 1823 - 1835
Combination immunotherapy including OncoVEXmGMCSF creates a favorable tumor immune micro-environment in transgenic BRAF murine melanoma Robyn D. GartrellZoë BlakeYvonne M. Saenger Original Article 09 January 2022 Pages: 1837 - 1849
Blocking GARP-mediated activation of TGF-β1 did not alter innate or adaptive immune responses to bacterial infection or protein immunization in mice Mélanie GaignageXuhao ZhangSophie Lucas Original Article Open access 01 January 2022 Pages: 1851 - 1862
Functional virus-specific memory T cells survey glioblastoma Jianfang NingNoah V. GavilPamela C. Rosato Original Article 10 January 2022 Pages: 1863 - 1875
Selection of antibody and light exposure regimens alters therapeutic effects of EGFR-targeted near-infrared photoimmunotherapy Ryuhei OkadaTakuya KatoHisataka Kobayashi Original Article 11 January 2022 Pages: 1877 - 1887
A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer Bangyou ZuoXiaobo YangHaitao Zhao Original Article 13 January 2022 Pages: 1889 - 1896
Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial Jifang GongJunning CaoLin Shen Original Article Open access 05 January 2022 Pages: 1897 - 1908
Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia Fernanda Marconi RoversiMaura Lima Pereira BuenoSara Teresinha Olalla Saad Original Article 18 January 2022 Pages: 1909 - 1921
Prognostic value, DNA variation and immunologic features of a tertiary lymphoid structure-related chemokine signature in clear cell renal cell carcinoma Wenhao XuChunguang MaDingwei Ye Original Article 19 January 2022 Pages: 1923 - 1935
Alterations of circulating lymphocyte subsets in patients with colorectal carcinoma Johanna WaidhauserPia NerlingerAndreas Rank Original Article Open access 20 December 2021 Pages: 1937 - 1947
Efficacy of immunotherapy beyond RECIST progression in advanced melanoma: a real-world evidence Anna Małgorzata CzarneckaPaweł SobczukPiotr Rutkowski Original Article 25 January 2022 Pages: 1949 - 1958
Efficacy of an ALDH peptide-based dendritic cell vaccine targeting cancer stem cells Fei LiaoJing ZhangQiao Li Original Article 31 January 2022 Pages: 1959 - 1973
Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer Nadja SalomonAbderaouf SelmiFulvia Vascotto Original Article Open access 31 December 2021 Pages: 1975 - 1988
Hypoxia-inducible factor-1 alpha expression is induced by IL-2 via the PI3K/mTOR pathway in hypoxic NK cells and supports effector functions in NKL cells and ex vivo expanded NK cells Emily CluffCarina C. MagdalenoNarendiran Rajasekaran Original Article Open access 09 January 2022 Pages: 1989 - 2005
Oral administration of a whole glucan particle (WGP)-based therapeutic cancer vaccine targeting macrophages inhibits tumor growth Liuyang HeYu BaiCui Tang Original Article 04 January 2022 Pages: 2007 - 2028
Vaccination against galectin-1 promotes cytotoxic T-cell infiltration in melanoma and reduces tumor burden Julia FemelLuuk van HoorenAnna-Karin Olsson Original Article Open access 11 January 2022 Pages: 2029 - 2040
A phase I dose-escalation, safety/tolerability, and preliminary efficacy study of the intratumoral administration of GEN0101 in patients with advanced melanoma Eiji KiyoharaAtsushi TanemuraYasufumi Kaneda Clinical Trial Report Open access 05 January 2022 Pages: 2041 - 2049
Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment Sophia B. StrobelDevayani MachirajuJessica C. Hassel Research Report Open access 23 December 2021 Pages: 2051 - 2056